

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>A61K 9/127</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/56728</b> <b>(43) International Publication Date:</b> 11 November 1999 (11.11.99)
<b>(21) International Application Number:</b> PCT/US99/04806 <b>(22) International Filing Date:</b> 5 March 1999 (05.03.99) <b>(30) Priority Data:</b> 60/083,911 1 May 1998 (01.05.98) US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 09/003,238 (CIP) Filed on 6 January 1998 (06.01.98) <b>(71) Applicant (for all designated States except US):</b> HARVARD SCIENTIFIC CORPORATION [US/US]; Suite 380, 100 North Arlington Avenue, Reno, NV 89501 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> SEE, Jackie, R. [US/US]; 4446 Los Reyes Court, Las Vegas, NV 89121 (US). <b>(74) Agent:</b> OLSTER, Kathleen, M.; Christie, Parker & Hale, LLP, P.O. Box 7068, Pasadena, CA 91109-7068 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PGE-1 CONTAINING LYOPHOLIZED LIPOSOMES FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION		
<b>(57) Abstract</b> <p>A method for the treatment of erectile dysfunction comprises instilling intra meatally an aqueous solution containing prostaglandin-containing liposomes, a lysing agent for lysing the liposomes, and a papaverine solution. A pharmaceutical composition for treating erectile dysfunction comprises a three-component system. The first component comprises a predetermined amount of prostaglandin-containing liposomes, preferably lyophilized. The second component comprises a predetermined volume of an aqueous solution containing a lysing agent, preferably PEG(9) octylphenyl ether, for lysing the liposomes. The third component comprises a papaverine solution. Dissolution of the prostaglandin-containing liposomes and addition of the papaverine solution to the mixture yields a liquid composition suitable for application to the penis, preferably intra meatally, to effect erection.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PGE-1 CONTAINING LYOPHILIZED LIPOSOMES FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION

### FIELD OF THE INVENTION

5 This invention relates to the treatment of erectile dysfunction, and more particularly to the intra meatal administration of prostaglandin-containing liposomes to effect tumescence and rigidity.

### BACKGROUND OF THE INVENTION

10 The male erectile response is a vascular effect initiated by neuronal action and maintained by a complex interplay between vascular and neurologic effects. Parasympathetic input allows erection by relaxation of trabecular smooth muscle and dilation of the Pilocene arteries of the penis. This leads to extension of the lacunar spaces and entrapment of blood by compressing  
15 venules against the tunica albuginea. Erectile dysfunction or impotence is a consistent inability to achieve or sustain an erection of sufficient rigidity for sexual intercourse. The degree of erectile dysfunction varies, and it ranges from a partial decrease in penile rigidity or the inability to sustain an erection to complete erectile failure.

Treatments for erectile dysfunction include vacuum constrictive devices, vascular surgery, penile prostheses, psychosexual therapy, hormonal therapy, and the administration of  
20 vasodilators. It has been found that direct injection of vasodilator substances into the corpora of the penis is a highly successful method for producing a rapid onset of erection in many patients. The most effective and well studied agents used in direct injection include papaverine hydrochloride, phentolamine, and alprostadil or prostaglandin E-1 (PGE-1). These have been used either singly or in combination. While generally effective, this procedure is often found to  
25 be psychologically disturbing, painful, traumatic or inconvenient as shown by a high rate of patient dropout. Moreover, infection, penile corporal fibrosis, fibrotic nodules, hypotension and priapism may ensue.

Vasodilator substances have also been administered through the urethra. This is described, for example, in U.S. Patent No. 4,801,578 to Voss, U.S. Patent No. 4,242,391 to  
30 Place, et al., and European Patent Application No. 0,357,581 to Kock.

Papaverine hydrochloride dilates both arterials and venules which results in venous leakage. Phentalomine affects sympathetic innervation which is not always the cause of erectile dysfunction. PGE-1 selectively dilates arteriolar and/or nerves thereby inducing vascular engorgement of the corpora cavernosa.

35 While prostaglandins, particularly prostaglandin E-1, have been shown to be effective in producing erection by direct needle injection into the corpora, the use of prostaglandins in treating erectile dysfunction has been limited due to their short shelf life. Prostaglandins are very unstable and are difficult to produce in a pharmaceutically stable formulation. For example, in

1 aqueous solution, prostaglandin E-1 has a shelf life of only approximately 90 seconds. This  
means that, to be useful, it must be dissolved and injected or applied immediately. For external  
or intrameatal applications, prostaglandins are not favored because substantial degradation  
occurs before enough prostaglandin can diffuse across the epidermis or urethral membrane into  
5 the corpora cavernosa to cause erection.

## SUMMARY OF THE INVENTION

The present invention provides pharmaceutical compositions and methods for treating  
erectile dysfunction. Preferred pharmaceutical compositions include a two component system,  
10 one component comprising prostaglandin-containing liposomes (also referred to as "liposomal  
PG") and a second component comprising an aqueous activator solution comprising chemical  
means for controllably lysing the liposomes to free the prostaglandin contained therein. To  
increase the shelf life of the product, the liposomal PG are preferably lyophilized. In a preferred  
embodiment, the prostaglandin is prostaglandin E-1 ("PGE-1"). Preferred means for controllably  
15 lysing the liposomes comprises an aqueous solution of a nontoxic detergent, preferably PEG(9)  
octylphenyl ether. To treat erectile dysfunction, the two components are mixed together to form  
a solution which is then applied to the penis, either externally or, more preferably, intra meatally,  
to produce a satisfactory erection.

In the method of the present invention for treating erectile dysfunction, a composition  
20 comprising liposomal PG is applied to the penis. Application may be external or, more  
preferably, intrameatal. If external, the composition may be in the form of an aqueous solution  
or a cream or ointment. If administered intra meatally, it is preferred that the composition be  
in the form of an aqueous solution. The amount of prostaglandin administered is preferably from  
about 0.25 mg to about 5 mg and more preferably from about 1 mg to about 2.5 mg. It is  
25 preferred that the solution be administered intrameatally in one or more doses of from about 0.5  
cc to about 1 cc.

In a preferred method of the invention, lyophilized liposomal PG is dissolved in an  
aqueous activator solution containing a detergent, preferably PEG(9) octylphenyl ether, to form  
an active aqueous mixture. The amount of liposomal PG in the solution is preferably selected  
30 to produce a solution containing from about 0.25 mg/cc to about 6 or more mg/cc prostaglandin  
and preferably from about 0.5 mg/cc to about 2 mg/cc. The concentration of detergent in the  
solution is preferably from about 0.02% to about 2%, and preferably from 0.05% to about 0.25%,  
by weight to thereby effect lysing of the liposome over a period of preferably not more than  
about 20 minutes, and more preferably not more than about 5 to 10 minutes, and even more  
35 preferably within about 2 to 5 minutes of mixing. After adding the liquid detergent to the  
lyophilized liposomal PG, the solution is vigorously shaken for 1 to 3 minutes, then the solution  
is allowed to clear, generally requiring 2 to 5 minutes. In a particularly preferred embodiment  
of the invention, papaverine is added to the active aqueous mixture, either before or after the

1 liposomal PG is dissolved in the active aqueous solution.

5 In a preferred method, the liposomal PG solution is administered intrameatally through a soft elongated 10 to 15 mm nipple. With the patient lying on his back, a thin elongated nipple is inserted into the urethra to a distance of about 1 cm to about 2 cm from the meatal opening of the penis, and a selected amount of the solution, preferably 0.5 to about 1 cc, is instilled through the nipple. The solution is instilled slowly to minimize leakage. Typically, onset of tumescence occurs within 1 to 3 minutes, with full tumescence reached within 5 to 10 minutes lasting 20 to 40 minutes or more. Multiple doses may be instilled, if needed, to produce a satisfactory erection for sexual intercourse. In an alternate embodiment, the lyophilized liposomal PG and 10 activator solution are mixed in the reservoir of a condom. Once the liposomal PG is dissolved, the condom is fitted over the penis and massaged to spread the liquid over the penis. Satisfactory erections are generally attained within 5 to 10 minutes.

#### BRIEF DESCRIPTION OF THE DRAWINGS

15 FIG. 1 is a side view of a preferred delivery system.

#### DETAILED DESCRIPTION

20 A particularly preferred pharmaceutical for the treatment of erectile dysfunction comprises a two-component system. The first component comprises dry lyophilized prostaglandin containing liposomes. The second component comprises an aqueous activator solution containing a liposomal lysing agent, preferably a detergent. It is further preferred that papaverine is added to the second component, either before or after the second component is combined with the first component.

25 As discussed in more detail below, the two components are combined in a specific manner to form an active aqueous mixture that can be applied to the penis of a patient to produce erection of the penis.

30 Prostaglandins suitable for use in the present invention include prostaglandin E (PGE), including PGE-1, PGE-2 and PGE-3, prostaglandin A (PGA), including PGA-1, prostaglandin F (PGF), including PGF-2, prostaglandin D (PGD), including PGD-2, prostacylins, thromboxanes, leukotrienes, 6-keto-PGE-1 derivatives, carbacyclin derivatives, PGD-2 derivatives and the like. PGE-1 and PGE-2 are the preferred prostaglandins, and PGE-1 is the most preferred prostaglandin.

35 The liposomes of the present invention may be made of any suitable phospholipid, glycolipid, derived lipid, and the like. Examples of suitable phospholipids include phosphatide choline, phosphatidyl serine, phosphatidic acid, phosphatidyl glycerin, phosphatidyl ethanolamine, phosphatidyl inositol, sphingomyelin, dicetyl phosphate, lysophosphatidyl choline and mixtures thereof, such as soybean phospholipids, and egg yolk phospholipids. Suitable glycolipids include cerebroside, sulphur-containing lipids, ganglioside and the like. Suitable

1 derived lipids include cholic acid, deoxycholic acid, and the like. The presently preferred lipid for forming the liposomes is egg phosphatidylcholine.

5 The liposomes may be formed by any of the known methods for forming liposomes and may be loaded with prostaglandin according to known procedures. Known methods for forming liposomal PG are described, for example, in PCT Application No. PCT/US88/01714 and European Patent Application No. EP 0,512,916A2, both assigned to the Liposome Company, and European Patent Application No. EP 0,416,527A2 assigned to the Green Cross Corporation, and the references disclosed in those applications, all of which are incorporated herein by reference. What is formed is an emulsion comprising liposomal PG. It is understood that, in addition to  
10 prostaglandin, the liposomes may be loaded with other drugs such as papaverine hydrochloride and/or phentolamine.

It is preferred that the liposomes used in the present invention have an average mean diameter from about 20 nm to about 1000 nm and preferably of from about 100nm to about 200 nm. An average mean diameter of about 140 nm is particularly preferred. Liposomes larger than  
15 about 1000 nm are not preferred because they are difficult to make. Liposomes smaller than about 20 nm are usable but not preferred because they are difficult to make.

Accordingly, the liposomes produced are preferably treated to reduce their size and to produce a homogeneous population. This may be accomplished by conventional techniques such as extrusion through a filter preferably of 100 to 500 nm pore size, the filter being either the  
20 straight path or tortuous path type. Other methods of size reducing the liposomes to a homogenous size distribution are ultrasonic exposure, the French press technique, hydrodynamic shearing, homogenization using, for example, a colloid mill or Gaulin homogenizer or microfluidization techniques. Microfluidization is presently preferred.

Microfluidization is described, for example, in U.S. Patent No. 4,533,254 to Cook, et al.,  
25 which is incorporated herein by reference. In a preferred microfluidization procedure, the liposomal emulsion is forced at high pressure through a small diameter opening and splattered onto a wall and then collected.

In a particularly preferred embodiment of the invention, the liposomes are passed one to ten and preferably four times through an M-110 Series Laboratory Microfluidizer manufactured  
30 by Microfluidics Corporation at a pressure of, e.g., 14000-16000 pounds per square inch to achieve a generally homogenous population of liposomes having an average mean diameter of about 140 nm.

The aqueous emulsion of liposomal PG is stable for days as compared to minutes for prostaglandins. To further stabilize liposomal PG, the emulsion is preferably lyophilized. It has  
35 been shown that lyophilized liposomal PG can be stored at room temperature for one half to three years without degradation of the liposomes or prostaglandin.

Lyophilization may be accomplished by any method known in the art. Such procedures are disclosed, for example, in U.S. Patent No. 4,880,836 to Janoff, et al., which is incorporated

herein by reference. Lyophilization procedures preferably include the addition of a drying protectant to the liposome suspension. The drying protectant stabilizes the liposomes so that the size and content are maintained during the drying procedure and through rehydration. Preferred drying agents are saccharide sugars including dextrose, sucrose, maltose, manose, galactose, raffinose, trehalose, lactose, and triose sugars which are preferably added in amounts of about 5% to about 20% and preferably about 10% by weight of the aqueous phase of the liposomal suspension. Dextrose, sucrose and maltose are presently preferred. Mannitol may be used in conjunction with any of the saccharides. Additional preservatives such as BHT or EDTA, urea, albumin, dextran or polyvinyl alcohol may also be used.

The activator solution comprises a liposome lysing means, which may be any chemical soluble in water that is capable of lysing the liposomes without degrading the prostaglandin and that is nontoxic and nonirritating in the concentration used to the patient. Preferred lysing means include detergents. Nonlimiting examples of suitable detergents include the sodium salt of cholic acid, dodecyl- $\beta$ -D-maltoside, lauryldimethylamine oxide, PEG(9) octylphenyl ether (Triton® X-100) and polysorbate 20 (Tween® 20). PEG(9) octylphenyl ether is presently preferred.

The concentration of lysing agent is important. If the lysing agent is too concentrated, the prostaglandin is released too early and is deactivated prior to absorption. If too little is used, an insufficient quantity of prostaglandin is released. Preferably, the concentration of lysing agent is selected to be the minimum amount capable of lysing the liposomes within the desired time after mixing, preferably within 20 minutes, more preferably within 5 to 10 minutes and even more preferably within about 2 to 5 minutes. It is desired to use the minimal effective amount of lysing agent to thereby minimize any potential irritation to the patient. An amount of from about 0.02% to about 2% or more by weight of detergent lysing agent has been found to be effective in lysing the liposomes. A range of from about 0.05% to about 0.25% is presently preferred as providing the best combination of optimal time for lysing the liposomes (2 to 5 minutes), and minimal irritation to the penis.

The prostaglandin-containing liposomes are contacted with the aqueous activator solution whereby the liposome lysing agent present in the solution lyses the prostaglandin-containing liposomes over a selected period of time to form an active aqueous mixture containing released prostaglandin. Preferably the prostaglandin-containing liposomes are dissolved in the aqueous activator solution directly. Alternatively, the prostaglandin containing liposomes are dissolved in an aqueous solution that can then be combined with the aqueous activator solution.

Papaverine is added to the active aqueous solution either before or after it is contacted with the liposomal PG. It has been found that the inclusion of papaverine increases the incidence of erectile response. Preferably the papaverine is added in the form of a solution. It is also preferred that the papaverine is added approximately 1 to 10 minutes, more preferably 2 to 5 minutes, after the liposomal PG is dissolved in the activator solution. The combined solution should then be immediately administered to the patient.

1 The papaverine solution preferably comprises papaverine dissolved in chlorobutanol. Preferably the papaverine is present in the form of papaverine hydrochloride, more preferably in 0.5% chlorobutanol. Preferably papaverine is added in an amount such that a single dose contains about 5 mg to about 30 mg, and more preferably about 10 mg to about 25 mg, of  
5 papaverine. Preferably the papaverine is present in the active aqueous mixture in an amount ranging from about 5 mg/cc to about 60 mg/cc, and more preferably in an amount ranging from about 10 mg/cc to about 50 mg/cc.

It is known that about 10 to 20  $\mu$ g of prostaglandin E-1 needle-injected directly into the corpora cavernosa causes a vasodilatory effect resulting in tumescence and rigidity.  
10 Accordingly, it is desired to use an amount of liposomal PG that results in at least about 10 to 20  $\mu$ m of prostaglandin crossing the meatal or urethral membrane into the corpora cavernosa. It has been found that approximately 1% to 5% of a 1 mg dose of prostaglandin E-1 diffuses across the urethral membrane into the corpora cavernosa.

Accordingly, a 1 mg dose of liposomal PGE-1 is presently preferred although higher doses  
15 of up to about 6 mg may be used. Doses higher than about 6 mg are not preferred because no additional benefit is seen. Doses as low as about 0.25 mg may also be effective in some individuals.

Due to the limited volume of the urethra, the dose of liposomal PG must be administered in a volume of no more than about 2 cc and preferably a volume of from about 0.5 to 1 cc of  
20 solution. Larger amounts are not preferred as there is a greater tendency toward leakage through the meatus. It is understood that multiple doses may be administered if needed.

To determine the amount of liposomal PG necessary to deliver the desired dose of prostaglandin, it was necessary to determine how much prostaglandin is present. Analysis using a standard prostaglandin E-2 ELISA test established that prostaglandin can be loaded into  
25 liposomes in amounts as high as 20% to 40% by weight. However, it is preferred that the prostaglandin be present in the liposomes in an amount of from about 2% to about 3% by weight. A particularly preferred lyophilized liposomal PG composition comprises 44 mg egg phosphotidylcholine, 75 mg maltose and 1 mg prostaglandin E-1.

It is presently preferred that the dissolved liposomal PG solution be administered intra  
30 meally. As used herein "intra meatal" administration refers to and includes administration of the solution in any portion of the ureter within the penis although administration of solution within the portion of the ureter extending through the meatus, i.e., within about 2 to 3 cm from the meatal opening is preferred.

A preferred delivery system for intra meatal administration of the dissolved liposomal PG  
35 is shown in Fig. 1 hereto. The delivery system comprises a plastic vial 10 containing the lyophilized liposomal PG and into which the activator solution (generally 1 cc) is introduced. The vial 10 has a screw-on cap (not shown) to seal the vial, which is then shaken vigorously to mix the contents and dissolve the lyophilized liposomal PG. After allowing the product to stand



1 for about 2 to 5 minutes, the cap is removed and a soft plastic or rubber nipple 12 is press fitted into the vial opening. The nipple 12 has a diameter of about 1 mm and a length of about 2 cm.

5 In accordance with a preferred method of the present invention using the delivery system shown in Fig. 1, the patient is positioned supine on his back. The nipple portion of the vial is then gently inserted into the opening of the urethra and held firmly in place. The vial is then squeezed, pushing a portion of the contents of the vial into the urethra. The expended portion is stroked toward the base of the penis to prevent leakage. This is repeated until the entire contents of the vial has been delivered. The meatal opening is then held shut for a period of, for example, 5 to 10 minutes during which time full tumescence and rigidity is typically reached.

10 An alternative delivery system comprises a conventional condom. The condom is partially unrolled and the lyophilized liposomal PG is placed in the reservoir of the condom. The aqueous activator solution is then introduced into the reservoir and the contents are mixed until the liposomal PG is dissolved. The condom is then rolled onto the penis which is then massaged to spread the liquid evenly over the penis. Full tumescence is generally reached within 5 to 10 minutes.

15 It is understood that a wide variety of modifications can be made to the described preferred embodiments of the products and processes without departing from the scope of the present invention. For example, while lyophilization is preferred for increasing shelf life, it is not necessary for the practice of the present invention. Likewise, while the presence of a lysing agent enables controlled release of the prostaglandin, the presence of a lysing agent is not required to practice the claimed method. In such an embodiment, it is preferred that the concentrations of prostaglandin in the liposomes be increased to assume that an adequate amount of prostaglandin is released after administration.

20 If administered externally, the activator "solution" may comprise a lotion or ointment as described, for example, in U.S. Patent No. 4,801,587 to Voss, et al., which is incorporated herein by reference.

25 The efficacy of the present invention is demonstrated by the following examples. As used therein, "level" or "grade" of erection means that amount of tumescence estimated by the patient or the doctor. It is expressed as a ratio, e.g., 2/10, where 10 means full tumescence.

30 "Tumescence" means the amount of vascular engorgement, both elongation and circumferential. It is estimated by the patient or doctor and expressed as a percentage of full or maximum tumescence. "Rigidity" means inability of the penis to buckle. It is estimated by the patient or doctor and expressed as a percentage of rigidity when full tumescence is achieved. "Turgidity" means the amount of circumferential enlargement. It is also estimated by the patient or doctor and is expressed as a percentage of the turgidity achieved at full tumescence.

## EXAMPLE 1

## PREPARATION OF LYOPHILIZED PGE-1 LIPOSOMES

Liposomal PGE-1 used in the patient studies described in the examples below was prepared according to the following procedure.

1. 2250 ml of water (double distilled) to beaker (Keep Cool) and set with a nitrogen sparge for at least 30 minutes.
2. Add 225 gms of maltose (Sigma M5885) to the water and mix until dissolved. Keep the nitrogen sparge going. Mixture at ph of 4.81.
3. In another beaker 10.59 gms of egg phosphatidylcholine (EPC) (Sigma) is combined with 8.38 ml of ethanol (anhydrous, Sigma E3884) and mixed until dissolved. To this add 67.5 mg of BHT and mix until dissolved. To this mixture add 2160 mg of PGE-1 and mix until dissolved. Use the remaining 4.19 ml of ethanol to rinse any remaining PGE-1 in the weighing container into the mixture.
4. Draw the ethanol solution into a 10 ml glass syringe and add to the maltose solution over 11 minutes with continued nitrogen sparge. Keep ph <7.0 (goes into microfluidizer at ph 4.81). Measure. Hand blade mixture. Keep everything cool 1.5 degrees C.
5. Microfluidizer. Four (4) passes through the microfluidizer 110F: 9,000 Units

	<u>Total Weight of Materials</u>	<u>Based on Previous Run</u>
	<u>to be Used*</u>	<u>(886 Units)*</u>
EPC	10.59 grams	107.573 grams
Maltose	225 grams	2,285.55 grams
Ethanol	12.57 ml	127.69 ml
BHT	67.5 mg	685.66 mg
PGE-1	2160 mg	21,941 grams
(USP)Water	2250 ml	22,855.5 ml
Pressure	16,000 PSI	
Caution-keep acidic, keep temp (melting point 115 degrees)		
Note-Maltose melting point 102-103 degrees Centigrade		

---

\* Multiplier + 10.158

6. Take 2.7 ml of the finished product and lyophilize in approximately 1,000 -6 ml Wheaton eye dropper bottles.

Lyophilization was accomplished in a lyophilizer according to the following cycle:

1. Shelf at  $\leq -45^{\circ}\text{C}$  for at least one (1) hour before loading.

2. Load product keep at  $\leq -45^{\circ}\text{C}$  for twelve (12) hours.
3. Vacuum to  $\sim 50\mu$ .
4. Shelf temperature at  $-28^{\circ}\text{C}$  to  $-20^{\circ}\text{C}$  for 59 hours.
5. Shelf temperature rose from  $-20^{\circ}\text{C}$  to  $-5^{\circ}\text{C}$  during subsequent ten (10) hours.
- 5 Visually product needed extra time at  $-20^{\circ}\text{C}$ .
6. Shelf reset at  $-22^{\circ}\text{C}$  and maintained at  $-22^{\circ}\text{C}$  to  $-18^{\circ}\text{C}$  for thirty-six (36) hours.
7. Shelf reset  $+25^{\circ}\text{C}$  and held at  $25^{\circ}\text{C}$  for 48 hours.

It is anticipated that the following lyophilization cycle will provide the same results in a shorter time.

1. Shelf to  $\leq -45^{\circ}\text{C}$  for at least one (1) hour before loading.
2. Load product, keep at  $\leq -45^{\circ}\text{C}$  for at least six (6) hours.
3. Vacuum to  $\leq 100\mu$ .
4. Shelf to  $-28^{\circ}\text{C}$  for 50 hours.
5. Shelf to  $+25^{\circ}\text{C}$  for 40-50 hours.

#### Examples 2-14

##### Patient Studies

The following are examples of the intra meatal administration to male patients suffering erectile dysfunction of compositions comprising PGE-1, PGE-1 containing liposomes in varying concentrations or a placebo.

#### Example 2

##### Patient History

The patient was a 47-year old white male suffering psychogenic impotence. The patient had no salient medical features, no allergies, no hospitalizations, and currently was taking no medications. Physical examination showed: pulse 70; respiration 16; blood pressure: 140/90; physically within normal limits.

##### Experimental Procedure

Trial No. 1: 10 cc of a solution containing 0.25% buffered acetate was introduced into a tube containing 2 mg of PGE-1 in the form of a white crystalline powder to achieve a concentration of 0.2 mg/cc. It was noted that there was an odor of vinegar. The white crystalline powder when mixed with the buffer solution did not completely dissolve. The particulate crystalline nature of the mixture did not change appreciatively with either time, mixing by shaking, or with increase of temperature to room temperature ( $72^{\circ}\text{F}$ ). One cc of the solution was drawn up into a dropper which was inserted into the urethral meatus of the patient wherein the solution was instilled. The patient noted stinging/burning sensation of the opening. It was not

possible to insert the entire volume into the urethra and an immeasurable amount of leakage occurred. No erection occurred. A second dosage using the same volume and milligram dosage of the white crystalline material was administered to the patient, with essentially the same results.

Trial No. 2: A second vial containing 4 mg of PGE-1 was mixed with 2 cc of the same buffer used in Trial No. 1 to achieve a concentration of 2 mg/cc. The crystalline particulate nature of the solution was again noted. One cc of the solution was instilled into the urethral meatus as in Trial No. 1. The patient again noted some slight stinging/burning with discomfort increasing with increase of pressure to the urethra upon filling with the solution.

Transient erectile activity was noted. The glans penis enlarged to 70% erect size (as recorded by the patient). Patient also noted the feeling of engorgement of the penis. The penile shaft engorged by 50% and elongation occurred of 50%. This transient effect lasted approximately 30 seconds. There was no rigidity of erection, only turgidity.

A second instillation of 1 cc did not provide any response by the patient except for complaint of stinging at the urethral opening and pressure from the instillation.

Phone report by patient after 3 hrs. Patient noted that he had a fullness sensation in the groin and penis, like he has had erection and sex. Patient noted no pain or residue from tests. He indicated that penis still feels engorged as if it were post coital. Only slight stinging sensation in the meatus.

### Example 3

#### Patient History

No relevant health history. Physical examination showed Height 5'9"; weight 165; blood pressure 142/98; pulse 88; physically within normal limits.

No prior sexual dysfunction.

#### Experimental Procedure

PGE-1 was added to 10 cc of a buffer solution containing 0.25% buffered acetate to make a solution of 4 mg of PGE-1 per cc of solution. All material appeared to dissolve in solution. The patient was put in supine position on examination table and 1/2 (0.5) cc of solution was instilled with an eye dropper into the urethra of the patient. A ring of K-Y jelly was put on the eyedropper 1 cm up the glass from tip so the meatus could be closed and the solution would not back flow or drip out. The patient was treated 4 times within a 30-minute interval, about every 7 minutes. No discomfort. No burning, either in urethra or meatus. No sensation of fullness in urethra or discomfort with insertion of material. Penis was observed over a 1 hour period. After 2 mg, no reaction. After 4 mg, some tumescence. After 6 mg slightly more engorgement. After 8 mg, a grade 2-3/10 erection was achieved but no more after next hour.

Patient contacted after 2 and 3 hour intervals. No further engorgement occurred.

## Example 4

Patient History

Health History: Cardiac disease (pericarditis) at 34. Hospitalized for 2 weeks. Right knee meniscectomy at 36. No current c.c. No current meds. No history of sexual dysfunction. Physical examination showed NAD within normal limits; blood pressure 130/82; pulse 80; weight 160; height 5'10".

Experimental Procedure

Crystalline liposomal PGE-1 was dissolved in buffer solution containing 2% detergent PEG(9) octylphenyl ether to form 2 mg PGE-1/cc solution. The patient was placed in a supine position and a thin 1-1/2 cm soft nipple was used to instill solution into the urethral meatus in 1/2 cc increments. The patient was instilled twice over a 10-minute period. The patient complained of slight meatal burning/stinging. Engorgement to the 2-3/10 erection grade level noted after second instillation. Patient subjectively reported some burning. He also noted a feeling of fullness in the groin, and that he felt it would be very easy to "get an erection" with sexual stimulation.

Post check after 2 and 3 hours: Patient reported after leaving that he masturbated to ejaculation to relieve sensation of fullness.

## Example 5

Patient History

This is the same patient who participated in the experiment procedure described in Example 4.

Experimental Procedure

A vial containing 500 mg lyophilized PGE-1 containing liposomes was diluted with 3 cc of a buffer containing 1% detergent PEG(9) octylphenyl ether to yield a solution containing 1 mg/cc PGE-1. With 5 minutes of vigorous shaking, the entire contents of the vial were dissolved and there was no particulate matter noted. There was no odor to the contents. The patient was placed in a supine position on an examination table and 0.5 cc of the solution was drawn into an eyedropper and administered intra meatally. A ring of K-Y jelly placed 1 cm up the eye dropper kept seepage to a minimum.

After the first instillation, there was no reaction, but the subject complained of burning sensation in the urethra. After 5 minutes a second dose of 0.5 cc was instilled and the patient achieved a 2-3/10 grade erection of transitory nature.

After a lapse of 4 minutes, a third dose of 0.5 cc of the solution was instilled and the subject achieved a 4-5/10 grade erection. After another 5 minutes, a fourth dose of 0.5 cc of the solution was instilled and the erection did not achieve more than a grade 4/10 quality. There was

1 only turgidity and not rigidity. The patient then stood up and the erection increased to a grade 7/10. He was asked to lie back down and the erection decreased to a grade 3/10. After 4 minutes he again stood up and the erection increased to 7/10 once again. The patient elected not to have any more instillations to the urethra at this time. One hour after the experiment the patient  
5 reported that the erection was still a grade 3/10. Two hours after the experiment, the patient reported that the erection was still a grade 3/10 and on his first voiding there was a burning sensation. Three hours after the experiment, all signs of engorgement had disappeared.

#### Example 6

##### Patient History

10 A 73 year-old male was the subject of this experiment. The patient had the sexual dysfunction of losing erections after approximately 3 minutes after penetration, but had no difficulty with ejaculation. His a.m. erections were grade 10/10, and he had no history of vascular insufficiency. Medical history that was pertinent was that he was taking Hytrin 2QD  
15 for blood pressure and Provocol for cholesterol. History was taken and physical examination was given. All within normal limits.

##### Experimental Procedure

20 A vial containing lyophilized PGE-1 containing liposomes was mixed with 8 cc of buffer comprising 1% detergent PEG(9) octylphenyl ether to make a solution containing 1 mg/cc PGE-1. One cc increments of the resulting solution were instilled for a total of 3 installations.

There was no response from the first two instillations. On the third installation, the patient obtained an erection of grade 7/10 and was sufficient for penetration. The right corpora cavernosa filled, and the spongiosa filled but the left did not fill, causing the penis to angle left  
25 due to a deficiency of left corporal filling. The patient complained of slight stinging after instillation and leakage was kept to a minimum by the previously described use to K-Y jelly.

#### Example 7

##### Patient History

30 The patient was a 52 year-old white male. The patient was given a full medical examination and there were no abnormal pathological findings. He has a six-year history of diabetes mellitus for which he takes Diabenase 250mg B.I.D. The patient does not smoke or drink. There are no other contributory health factors. The patient noted the slow onset of impotence approximately 2 years prior to this evaluation. The patient is in a stable marriage of  
35 20 years duration, and he and his wife attempt intercourse approximately once per week with 25% success rate.

### Experimental Procedure

To a vial having a nipple tip as shown in FIG. 1 containing lyophilized liposomal PGE-1 was introduced one cc of a buffer, containing 0.5% detergent PEG(9) octylphenyl ether to make a solution containing 1 mg/cc PGE-1. The patient was put in a supine position on the examination table and a bead of K-Y jelly was placed on the nipple tip of the vial container. The mixture was combined 10 minutes prior to patient instillation. The nipple tip was inserted into the urethral meatus of the patient and the entire contents of the container were instilled slowly. The meatal opening was then held closed to prevent leakage for the next five minutes.

This patient obtained 100% tumescence of the penis with about 50% rigidity. He noted that at no time did his penis get more erect than this on its own. The patient was contacted after two hours and stated that, after he was erect for 1.5 hours, he elected to masturbate. The erection was sufficient and after ejaculation, immediate detumescence followed.

### Example 8

#### Patient History

This patient was a 48 year-old white male. The patient was given a full medical examination and there were no abnormal pathological findings. The patient had a six-year history of diabetes mellitus for which he takes N.P.H. 40 $\mu$  p.m., Seldane 20 mg, Glucatorl 5 mg a.m. The patient did not smoke or drink. There are no other contributory health factors. The patient noted the slow onset of impotence approximately 2 years prior to the evaluation. The patient indicated a stable marriage of 10 years duration wherein intercourse was attempted approximately once per week with 50% success rate.

#### Experimental Procedure

To a vial having a nipple tip and containing 500 mg lyophilized liposomal PGE-1 was introduced 1 cc buffer containing 0.1% detergent PEG(9) octylphenyl ether to make a solution containing 1 mg/cc PGE-1. The patient was put in a supine position on the examination table and a bead of K-Y jelly was placed on the nipple tip of the vial. The mixture was combined 10 minutes prior to patient instillation. The nipple tip was inserted into the urethral meatus and the entire contents of the container were instilled slowly. The meatal opening was then held closed to prevent leakage for the next five minutes. After pressure was released approximately 90% of the mixture was expelled.

This patient obtained a 50% tumescence of the penis with about 20% rigidity. The patient noted that at no time did his penis get more erect than this on his own.

## Example 9

Patient History

The patient was a 67 year-old white male. The patient was given a full medical examination, and there were no abnormal pathological findings. The patient suffers from "hay fever" and takes Seldane D. The patient also has high cholesterol and is treated with Lipid 1 QD. The patient does not smoke or drink. There are no other contributory health factors. The patient was hospitalized once at age 32 for kidney stones. Blood pressure 150/78, SMAC, CBC, UA, WNL. The patient noted the slow onset of impotence approximately 4 years prior to the evaluation. The patient is in a stable marriage of 26 years duration and intercourse is attempted approximately once per week with 50% success rate.

Experimental Procedure

To a vial having a nipple tip and containing 500 mg lyophilized liposomal PGE-1 was introduced 1 cc buffer containing 0.025% detergent PEG(9) octylphenyl ether to make a solution containing 0.5 mg/cc PGE-1. The patient was put in a supine position on the examination table and a bead of K-Y jelly was placed on the nipple tip of the vial. The mixture was combined 10 minutes prior to patient instillation. The nipple tip was inserted into the urethral meatus of the patient and the entire contents of the container were instilled slowly. The meatal opening was then held closed to prevent leakage for the next five minutes.

This patient obtained a 50% tumescence of the penis with 0% rigidity. The patient reports that his erections with masturbation and a.m. erections are occasionally 10/10.

## Example 10

Patient History

This patient is a 55 year-old white male. The patient was given a full medical examination and there were several pathological findings. In 1982 he had an aortic heart valve replacement and in 1949 he had an appendectomy and tonsillectomy. Physical examination reveals an aortic click. There is no pedal edema and his blood pressure is within the normal limits of 120/80. However, he has been treated with Lanoxin 0.25 mg; Zestril 10 mg; and Mevacor 20 mg. He reports that his blood pressure is 160/110 when he is not under treatment. He also has a large right inguinal hernia for which he reports that he is undergoing surgery next week. The patient does not smoke. He does suffer from high cholesterol which is controlled by Mevacor. He drinks moderately, i.e., one beer per day. He has been hospitalized on several occasions for asthma, pneumonia, and suffered from very severe depression following his aortic heart valve replacement. The patient reports that he is also capable at the present time of achieving grade 8/10 to 9/10 erections with attempts at intercourse but generally these subside to 0/10 with penetration or prior to penetration. Attempts at intercourse are usually once per month. The patient reports masturbatory activity twice a week with 8/10 erections throughout



the entire course of masturbation, with a 9/10 erection at ejaculation. He reports that the problem of impotence has existed for four years and his marriage of 29 years appears to be intact. He has three male children who are all in good health. Salient historical features are that his father died from a stroke and his brother has kidney disease. His father also had hypertension prior to the stroke.

#### Experimental Procedure

A vial having a nipple tip and containing 1 cc of a placebo of 0.25% by weight PEG(9) octylphenyl ether was provided. The patient was put in a supine position on the examination table and a bead of K-Y jelly was placed on the nipple tip of the vial. The nipple tip was inserted into the urethral meatus and the entire contents of the vial were instilled slowly. The meatal opening was then held closed to prevent leakage for the next five minutes. There did, however, during the insertion appear to be leakage of approximately one-half of the contents.

The patient obtained zero degree of tumescence of the penis and zero degree of rigidity. He was then examined 10 minutes and 20 minutes post insertion and was asked to call back in three hours. There was no tumescence noted at any time. The patient had no negative results and reported an absence of any adverse side effects. He did say that he had some slight flushing following the instillation but that this has been a symptom he has suffered with for several years.

#### Example 11

##### Patient History

This is a 58-year-old white male who presented with a chief complaint of intermittent episodic impotence for approximately seven to ten years. At the present time he is divorced but has a current sexual partner, age 52. He attempts intercourse twice a week and uses a vacuum device supplied by Kaiser to obtain an erection. With genital oral sex he obtains a 7/10 erection. He obtains normal nocturnal erections. His SMAC, CBC, UA are all within normal limits and there appear to be no abnormal physiologic difficulties. At the present time he has no medical history or any salient historical features. He had a vasectomy in 1982, left meniscectomy in 1958, a left hydrocele repair in 1955, and a pilonidal cyst repair. There are no other medical history chief complaints. He was given a full medical examination. There are no other contributory health factors that were noted on physical examination.

##### Experimental Procedure

To a vial containing 500 mg lyophilized liposomal PGE-1 was introduced one cc buffer comprising 1 mg/cc PGE-1. The patient was put in a supine position on the examination table and a bead of K-Y jelly was placed on an eyedropper. The mixture was combined ten minutes prior to patient instillation. The mixture was then drawn into the eyedropper and the eyedropper was inserted into the urethra to a distance of approximately 2.5 cm. The eyedropper was inserted

1 into the urethral meatus and the entire contents were instilled slowly. The meatal opening was then held closed to prevent leakage for the next five minutes.

The patient obtained approximately 80 to 90 percent tumescence with 50 to 60 percent rigidity. He reported back within two hours and reported a "fullness" type of feeling in the groin. He masturbated to relieve this pelvic congestion and noted that the erection subsided within the next 30 minutes, but held at about the 80 percent level during the next two hours, which the patient noted was sufficient for penetration had an available partner been present.

## Example 12

### Patient History

This patient is a 68-year-old male who presented with a chief complaint of intermittent episodic impotence for approximately ten years. The patient was given a full medical examination and there were no abnormal pathological findings. His father died at age 87 of a stroke. His mother died at age 93 of hypertension. There is no familial history for any other diseases. He has a 56-year-old sister who is in good health. The patient presently takes Hytrin for his prostatic hypertrophy. He has no other medical difficulties. He does not smoke. He drinks 4 ounces of alcohol per week and two cups of coffee per day. The patient is not married and has not been married for the last 15 years; however, he does have multiple female partners. The patient obtains a 10/10 grade a.m. erection and a 10/10 p.m. erection. The patient has not had nocturnal penile tumescence monitoring but his last SMAC, CBC and urinalysis were within normal limits and his last electrocardiogram was within normal limits.

The patient has been using papaverine and Regitine for approximately four years on a two to three time per week basis and has been using papaverine, Regitine and prostaglandin injections for approximately one year. The patient travels to Brazil on an infrequent basis where he uses this daily. He has not suffered from priapism.

### Experimental Procedure

To a vial containing 500 mg lyophilized liposomal PGE-1, was introduced 1 cc buffer comprising 0.25% detergent PEG(9) octylphenyl ether making a solution comprising 1 mg/cc PGE-1. The patient was put in a supine position on the examination table and a bead of K-Y jelly was placed on the eyedropper tip to contain the mixture in the urethra. The mixture was then instilled into the urethra approximately 10 minutes after mixture. The meatal opening was then held closed to prevent further leakage for the next 5 minutes.

After the patient sat upright, approximately one-half of the mixture leaked from the urethra. However, the patient went on to obtain 80 percent tumescence with 50 percent rigidity. Ten minutes after this was noted, the patient had a 100 percent erection with full rigidity and full tumescence.

## Example 13

Patient History

This patient is a 53-year-old white male. The patient was given a full medical examination and there were no abnormal physiologic findings. At the time of examination, he suffered from hemorrhoids, frequent headaches described as nonmigrainous but as tension and back pain for which he has a long history of lower back pain. He also had a disc removal in 1984 of the C7 disc space. He has frequent rashes. Childhood diseases include chickenpox, measles and mumps. He currently drinks one to four drinks per day and smokes about one-half pack of cigarettes per day. Blood pressure was 130/82.

Experimental Procedure

A vial containing 1 cc of a placebo of 0.25% by weight PEG(9) octylphenyl ether was provided. The patient was put in a supine position on an examination table and a very small diameter urethra was noted which barely accommodated the tip of the eye dropper vial. Instillation of the solution was begun, but the patient immediately complained of pain in the meatus and the procedure was stopped for approximately two minutes. The instillation was thereafter continued and approximately half a dropper full of solution was instilled into the urethra before this patient again complained of pain and the procedure was stopped for approximately five minutes. Instillation was resumed and one more dropper full was instilled, but there was massive leakage of the first dropper out of the urethra. The patient did not wish to proceed further with the test at this time since he was experiencing discomfort. There was no erection noted and the meatus was held shut for five minutes to keep solution contained in the urethra intact.

The patient received no erection at time of instillation of the solution and at 20 minutes post experiment the penis was essentially as it was prior to the experiment. There was never any feeling of fullness on the patient's part or any subjective feeling of erection.

The results of Examples 2-13 are tabulated below in Table 1

TABLE 1

Example	Dose of PGE-1 (nonliposomal)	Dose of PGE-1 (Liposomal)	Conc. of Detergent	Summary of Results
2 (Trial #2)	0.2 mg	-	-	Transient effect: 70% erection; 50% engorgement; 50% elongation: duration 30 sec.
3	2 mg x 2 = 4 mg	-	-	Grade 2-3/10 erection
4	-	1 mg x 2 = 2 mg	2%	Grade 2-3/10 erection
5	-	0.5 mg x 4 = 2 mg	1%	Grade 4-5/10 erection supine; grade 7/10 erection standing; grade 3/10 after 2 hours.
6	-	1 mg x 3 = 3 mg	0.5	Grade 7/10 erection.
7	-	1 mg	0.25	100% tumescence; 50% rigidity; erect for 1.5 hrs.
8	-	1 mg	0.1	50% tumescence; 20% rigidity.
9	-	0.5 mg	0.025	50% tumescence; 0% rigidity.
10	-	-	-	0% tumescence; 0% rigidity.
11	-	1 mg	0.25	90% tumescence; 50-60% rigidity, 30 min. full erection; 2 hr. 80% erection.
12	-	1 mg	0.25	80% tumescence; 50% rigidity.
13	0	0	-	0% tumescence; 0% rigidity.

## Example 14

Lyophilized liposomal PGE-1 was prepared as in previous examples. Papaverine solution was prepared in 2 ml ampoules by adding 10 to 30 mg papaverine hydrochloride to 60 mg of 0.5% chlorobutanol. The lyophilized liposomal PGE-1 was diluted with a detergent solution.

The papaverine solution was added to the lyophilized liposomal PGE-1 approximately 2-5 minutes after the detergent was added. The mixture was shaken then administered to a patient intrameatally. It was found that the inclusion of papaverine resulted in a better erectile response, particularly in patients who did not have a satisfactory erectile response from intrameatal administration of liposomal PGE-1 alone.

## 1 WHAT IS CLAIMED IS:

1. A method for treating a male patient suffering erectile dysfunction comprising:  
contacting a predetermined amount of prostaglandin-containing liposomes with an  
aqueous activator solution comprising a liposome lysing agent, whereby the liposome lysing  
agent lyses the prostaglandin-containing liposomes over a select period of time to thereby form  
an active aqueous mixture containing released prostaglandin;

adding papaverine solution to the active aqueous solution before or after contacting  
the active aqueous solution with the prostaglandin-containing liposomes; and

during the period that the released prostaglandin is active, applying an effective  
amount of the active aqueous mixture containing released prostaglandin and the papaverine  
solution to the penis of the patient for a time sufficient to produce erection of the penis.

2. A method as claimed in claim 1 wherein the liposomes of the predetermined  
amount of prostaglandin-containing liposomes are lyophilized.

3. A method as claimed in claim 2 wherein the prostaglandin-containing liposomes  
contain prostaglandin E-1.

4. A method as claimed in claim 2 wherein the active aqueous mixture containing  
released prostaglandin is applied to the penis of the patient intra-meatally.

5. A method as claimed in claim 4 wherein the active aqueous mixture containing  
released prostaglandin is applied in a volume of from about 0.5 cc to about 1 cc.

6. A method as claimed in claim 2 wherein the prostaglandin is present in the active  
aqueous mixture applied to the penis in an amount up to about 6 mg/cc.

7. A method as claimed in claim 2 wherein the prostaglandin is present in the active  
aqueous mixture applied to the penis in an amount from about 0.5 mg to about 2.5 mg.

8. A method as claimed in claim 2 wherein the liposomes have a mean average  
diameter of from about 20 nm to about 1000 nm.

9. A method as claimed in claim 2 wherein the liposomes have a mean average  
diameter of from about 100 nm to about 200 nm.

10. A method as claimed in claim 2 wherein the liposome lysing agent is a detergent.

1           11. A method as claimed in claim 10 wherein the detergent is present in the aqueous  
activator solution in an amount of from about 0.02% to about 2% by weight.

5           12. A method as claimed in claim 10 wherein the detergent is present in the aqueous  
activator solution in an amount of from about 0.05% to about 0.25% by weight.

10           13. A method as claimed in claim 10 wherein the detergent is selected from the group  
consisting of the sodium salt of choleic acid, dodecyl- $\beta$ -D-maltoside, lauryldimethylamine oxide,  
PEG(9) octylphenyl ether, polysorbate 20 and mixtures thereof.

14. A method as claimed in claim 10 wherein the detergent is PEG(9) octylphenyl  
ether.

15           15. A method as claimed in claim 2 wherein the lysing agent lyses substantially all of  
the liposomal PG within about 20 minutes after being contacted with the dissolved  
prostaglandin-containing liposomes.

20           16. A method as claimed in claim 2 wherein the lysing agent lyses substantially all of  
the liposomal PG within about 5 to about 10 minutes after being contacted with the dissolved  
prostaglandin-containing liposomes.

25           17. A method as claimed in claim 2 wherein the lysing agent lyses substantially all of  
the liposomal PG within about 2 to about 5 minutes after being contacted with the dissolved  
prostaglandin-containing liposomes.

18. A method as claimed in claim 2 wherein the papaverine is added in the form of a  
papaverine solution.

30           19. A method as claimed in claim 18 wherein the papaverine solution comprises  
papaverine hydrochloride.

20. A method as claimed in claim 18 wherein the papaverine solution comprises  
chlorobutanol.

35           21. A method as claimed in claim 5 wherein the papaverine is present in the active  
aqueous mixture in an amount ranging from about 5 mg to about 30 mg.

22. A method as claimed in claim 5 wherein the papaverine is present in the active aqueous mixture in an amount ranging from 10 mg to 25 mg.

23. A pharmaceutical kit for use in the treatment of male erectile dysfunction comprising:

a first component comprising a predetermined amount of liposomal PG;

a second component different from the first component comprising a predetermined volume of aqueous activator solution containing a liposomal lysing agent for lysing liposomal PG to release prostaglandin;

a third component different from the first and second components comprising papaverine;

whereby mixture of the first, second and third components results in a liquid composition containing released prostaglandin that can be applied to the penis to effect erection of the penis.

24. A pharmaceutical kit as claimed in claim 23 wherein the liposomes of the liposomal PG are lyophilized.

25. A pharmaceutical kit as claimed in claim 24 wherein the liposomal PG comprises prostaglandin E-1.

26. A pharmaceutical kit as claimed in claim 24 wherein the predetermined amount of liposomal PG and predetermined volume of aqueous activator solution are selected to achieve a concentration of PG in the liquid composition of from about 0.25 mg/cc to about 6 mg/cc when substantially all of the prostaglandin has been released from the liposomal PG.

27. A pharmaceutical kit as claimed in claim 24 wherein the predetermined amount of liposomal PG and predetermined volume of aqueous activator solution are selected to achieve a concentration of PG in the liquid composition of from about 0.5 mg/cc to about 2.5 mg/cc when substantially all of the prostaglandin has been released from the liposomal PG.

28. A pharmaceutical kit as claimed in claim 24 wherein the liposomes of the liposomal PG have a mean average diameter of from about 20 nm to about 1000 nm.

29. A pharmaceutical kit as claimed in claim 24 wherein the liposomes of the liposomal PG have a mean average diameter of from about 100 nm to about 200 nm.

30. A pharmaceutical kit as claimed in claim 24 wherein the liposomal lysing agent is

1 a detergent.

5 31. A pharmaceutical kit as claimed in claim 24 wherein the liposomal lysing agent is a detergent selected from the group consisting of the sodium salt of cholic acid, dodecyl- $\beta$ -D-maltosile, lauryldimethylamine oxide, PEG(9) octylphenyl ether, polysorbate 20 and mixtures thereof.

10 32. A pharmaceutical kit as claimed in claim 24 wherein the liposomal lysing agent is PEG(9) octylphenyl ether.

33. A pharmaceutical kit as claimed in claim 30 wherein the detergent is present in the second component in an amount of from about 0.02% to about 2% by weight.

15 34. A pharmaceutical kit as claimed in claim 30 wherein the detergent is present in the second component in an amount of from about 0.05% to about 0.25% by weight.

35 35. A pharmaceutical kit as claimed in claim 24 wherein the papaverine is in the form of a papaverine solution.

20 36. A method as claimed in claim 35 wherein the papaverine solution comprises papaverine hydrochloride.

25 37. A method as claimed in claim 35 wherein the papaverine solution comprises chlorobutanol.

30 38. A pharmaceutical kit as claimed in claim 24 wherein the predetermined amount of liposomal PG, predetermined volume of aqueous activator solution and papaver are selected to achieve a concentration of papaver in the active aqueous mixture of from about 5 mg/cc to about 60 mg/cc.

35 39. A pharmaceutical kit as claimed in claim 24 wherein the predetermined amount of liposomal PG, predetermined volume of aqueous activator solution and papaver are selected to achieve a concentration of papaver in the active aqueous mixture of from about 10 mg/cc to about 50 mg/cc.



1/1

*Fig. 1*



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/04806

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 9/127

US CL : 424/450; 514/559

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/450; 514/559

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
NONE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,482,039 A (PLACE) 09 January 1996, abstract, columns 3-5 and claims.	1-39
A	US 4,955,878 A (SEE et al.) 11 September 1990, abstract and claims.	1-39

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A document defining the general state of the art which is not considered to be of particular relevance	*X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E earlier document published on or after the international filing date	*Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A document member of the same patent family
*O document referring to an oral disclosure, use, exhibition or other means	
*P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
03 MAY 1999

Date of mailing of the international search report  
27 MAY 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

GOLLAMUDI S KISHORE

Telephone No. (703) 308-1235